[Radiosensitization induced by vemurafenib]

Abstract

The recent use of vemurafenib, a specific inhibitor of BRAF, has led to a significant improvement in disease-free survival and overall survival of patients treated for a BRAF-mutated metastatic melanoma. This new class of drugs is not devoid of side effects, including skin effects. In particular, its association with concomitant radiotherapy should be taken into consideration, vemurafenib appearing to be radiosensitizer. The radiation oncologist must be aware of this potential toxicity, which is not uncommon in clinical practice.

Keywords: Melanoma; Mélanome; Phénomène de rappel; Radiation recall; Radiation therapy; Radiosensibilisation; Radiosentitization; Radiothérapie; Vemurafenib; Vémurafénib.